inClinico is a platform for Data-driven multimodal forecast of single clinical trial's probability of success (PoS). inClinico utilizes massive amounts of data about the targets, diseases, clinical trials, and even scientists involved with the study at the preclinical and clinical stages
Predict clinical trials success rate
Recognize the weak points in trial design
Adopt the best practices in the industry
Recognize the weak points in trial design
Adopt the best practices in the industry
Clinical risk assessment and portfolio triage
Customer profiles & use cases
Research on general red flags
Post-mortem analysis on
failed project for possible revival
failed project for possible revival
AI-augmented trial design-
endpoints, sites, eligibility
endpoints, sites, eligibility
Clinical researchers &
developers
developers
Investment portfolio
de-risking
de-risking
Search for the assets to
invest in
invest in
Buy-side analysts at
pharma-focused funds
pharma-focused funds
Pharmaceutical portfolio
de-risking
de-risking
Competitive analysis
Technical due diligence for
Mergers and Acquisitions, licensing and partnerships
Mergers and Acquisitions, licensing and partnerships
BD&L executives at
pharma companies
pharma companies
inClinico for therapeutic pipeline due diligence
1. Proprietary ML algorithms for information
extraction & data harmonization
2. Comprehensively harmonized and curated public data
3. Advanced NLP system with a feedback loop from
industry experts
4. Large preclinical data feed from CROs
extraction & data harmonization
2. Comprehensively harmonized and curated public data
3. Advanced NLP system with a feedback loop from
industry experts
4. Large preclinical data feed from CROs
Advanced AI modelling platform powered by multimodal data
1. Probabilities of success based on different modalities
2. Granular interpretation of the predictions
3. Industry-wide success rate analysis
2. Granular interpretation of the predictions
3. Industry-wide success rate analysis
Individual clinical trial reports
1. Clinical trials prioritized by probabilities of success
2. Report covers clinical trial sponsors with details on their financials
3. Leverage derived probabilities and estimate NPV more precisely
to inform licensing and investment decisions
2. Report covers clinical trial sponsors with details on their financials
3. Leverage derived probabilities and estimate NPV more precisely
to inform licensing and investment decisions
Summary report with benchmarked pharmaceutical catalysts
inClinico for the clinical trial design enhancement
1. Trial structure - blinding, randomization and cohorts
2. Patient eligibility criteria
3. Endpoints
4. Clinical site information
2. Patient eligibility criteria
3. Endpoints
4. Clinical site information
inClinico extracts meaningful
representations from clinical trial protocol
representations from clinical trial protocol
1. Which details were the most important for the model prediction
2. Exact quantified influence of the each feature as well as feature groups
2. Exact quantified influence of the each feature as well as feature groups
Get interactive report on the clinical protocol details impact
1. Simulate alternative designs and get detailed reports
2. Choose the best design aligned with the expert knowledge
and data-driven recommendations
2. Choose the best design aligned with the expert knowledge
and data-driven recommendations
Get actionable insights into how to
change the clinical protocol to improve the probability of success
change the clinical protocol to improve the probability of success
Data Source
5M OMICs data samples
A full spectrum of transcriptomics, genomics, epigenomics, proteomics, single cell data
generated by the scientific community
generated by the scientific community
30M Publications
Published biomedical research results
3M Grants
Life sciences research grant funding
3.8M Patents
Patents covering the life sciences industry.
342K Clinical Trials
Explore extra knowledge related to the clinical trials design
13K Drugs
Drugs from Phase 1 of clinical trial
till Launched phase
till Launched phase
News
This website uses cookies to ensure you get the best experience
OK
